|By Marketwired .||
|September 3, 2014 04:30 PM EDT||
VANCOUVER, BC--(Marketwired - September 03, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) today announced that Wanbang Biopharmaceuticals has successfully completed another study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes.
The pharmacokinetic (PK) study of SBM-TFC-039 confirms an excellent oral bioavailability of SBM-TFC-039. Bioavailability refers to the drug's ability to be absorbed into the body. The results are in accordance with results of an earlier study conducted by Sirona Biochem. The drug was administered as a single dose in SD rats. The first milestone of the license agreement with Wanbang Biopharmaceuticals is expected after the next scheduled study, assessing toxicology in rats during a 14 day test. This will trigger a second payment to Sirona from Wanbang Biopharmaceuticals as part of the $9.5M in upfront and milestone payments.
"These results provide further evidence that we have an excellent compound for the treatment of Type 2 diabetes," said Dr. Howard Verrico, CEO. "Good bioavailability of a drug equates to lower dosing. It's a win for us in terms of the development of our SGLT2 Inhibitor."
About Wanbang Biopharmaceuticals
Wanbang Biopharmaceuticals is the leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes.
Wanbang Biopharmaceuticals is a subsidiary of Shanghai Pharmaceutical Group which is listed on the Shanghai Stock Exchange. Fosun Pharma, one of the major shareholders of Sinopharm Group, the largest drug distributor in China, is part of Fosun International, the leading non-state owned enterprise group in China which is listed on the Hong Kong Stock Exchange.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Email: [email protected]
Aug. 28, 2016 09:30 AM EDT Reads: 756
Aug. 28, 2016 09:30 AM EDT Reads: 693
Aug. 28, 2016 07:30 AM EDT Reads: 769
Aug. 28, 2016 07:00 AM EDT Reads: 2,393
Aug. 28, 2016 03:30 AM EDT Reads: 2,356
Aug. 28, 2016 02:00 AM EDT Reads: 1,780
Aug. 28, 2016 01:45 AM EDT Reads: 2,161
Aug. 28, 2016 01:30 AM EDT Reads: 2,099
Aug. 28, 2016 01:00 AM EDT Reads: 2,969
Aug. 28, 2016 12:15 AM EDT Reads: 1,839
Aug. 27, 2016 11:00 PM EDT Reads: 4,011
Aug. 27, 2016 08:45 PM EDT Reads: 2,364
Aug. 27, 2016 08:45 PM EDT Reads: 1,784
Aug. 27, 2016 06:00 PM EDT Reads: 3,108
Aug. 27, 2016 05:15 PM EDT Reads: 1,589